Vaccine technologies company TapImmune has reported that positive interim safety analysis was achieved in breast cancer patients treated with HER2/neu antigens.

The analysis conducted on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, did not establish any serious adverse events.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

TapImmune CEO Glynn Wilson said obtaining positive interim data is an important milestone for the programme.

"The analysis conducted on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, did not establish any serious adverse events."

"As we move through clinical development it is essential that we clear these early safety hurdles and move towards development of our complete HER2/neu vaccine," Wilson said.

The company will now progress the treatment of the remaining 17 patients in the Phase I study.

See Also:

HER2/neu Class II antigens show high affinity binding to human major histocompatibility complex (MHC) proteins for around 84% of the population, making it potentially applicable to a wide range of HER2/neu patients compared to other approaches.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Breast cancer patients who finished standard Herceptin-based therapy and are at risk of disease recurrence are participating in the trial.

Safety and immunogenicity are the primary endpoints of the study

TapImmune has an exclusive option to license the antigen technology at the end of Phase I.